Semaglutide activates GLP-1 receptors only, while tirzepatide is a dual GIP/GLP-1 receptor agonist, activating two complementary pathways involved in blood sugar regulation and appetite control
Eligible Aetna Medicare Part D enrollees can get Wegovy for a $50 monthly copay through the Medicare GLP-1 Bridge program
When the balance of your gut bacteria shifts, it can either help your body adapt smoothly or set the stage for prolonged digestive dysfunction
This represents a shared decision-making opportunity between patient and providers
Research indicates that rapid discontinuation can trigger metabolic rebound, increased appetite, and weight regain in 40-60% of users within weeks
For people who have struggled for years with weight, stigma, food noise and metabolic illness, the moralizing tone around these drugs can be cruel